

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO § 240.13d-2

Vascular Biogenics Ltd.

(Name of Issuer)

Ordinary Shares, par value NIS 0.01

(Title of Class of Securities)

M96883109

(CUSIP Number)

Ilan Lior
General Counsel
Aurum Group
16 Abba Hillel Road
Ramat Gan 5250608, Israel
Tel +972-3-576-2424

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

December 31, 2014

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	NAMES OF REPORTING PERSONS Aurum Ventures M.K.I. Ltd.		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) <input type="radio"/> (b) <input type="radio"/>		
3.	SEC USE ONLY		
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Israel		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 4,254,778	
	6.	SHARED VOTING POWER 0	
	7.	SOLE DISPOSITIVE POWER 4,254,778	
	8.	SHARED DISPOSITIVE POWER 0	
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,254,778		
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)		
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 21.4% (1)		
12.	TYPE OF REPORTING PERSON (see instructions) CO		

(1) Percentage is based on 19,898,674 Ordinary Shares of the Issuer that were issued and outstanding as of January 4, 2015 (which information appeared in the Issuer's proxy statement, dated January 6, 2015, for its extraordinary general meeting of shareholders that took place on February 11, 2015, which was annexed as Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K furnished by the Issuer to the SEC on January 6, 2015).

1.	NAMES OF REPORTING PERSONS Morris Kahn	
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) <input type="radio"/> (b) <input type="radio"/>	
3.	SEC USE ONLY	
4.	CITIZENSHIP OR PLACE OF ORGANIZATION	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER
	6.	SHARED VOTING POWER 4,254,778
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER 4,254,778
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,254,778	
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)	
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 21.4% (1)	
12.	TYPE OF REPORTING PERSON (see instructions) IN	

(1) Percentage is based on 19,898,674 Ordinary Shares of the Issuer that were issued and outstanding as of January 4, 2015 (which information appeared in the Issuer's proxy statement, dated January 6, 2015, for its extraordinary general meeting of shareholders that took place on February 11, 2015, which was annexed as Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K furnished by the Issuer to the SEC on January 6, 2015).

Item 1.**(a) Name of Issuer**

Vascular Biogenics Ltd.

(b) Address of Issuer's Principal Executive Offices

6 Jonathan Netanyahu St., Or Yehuda, Israel 60376

Item 2.**(a) Name of Person Filing:**

This Statement of Beneficial Ownership on Schedule 13G (this "Statement"), is being filed by each of:

(i) Aurum Ventures M.K.I. Ltd. (the "Reporting Entity")

(ii) Morris Kahn (the "Reporting Individual")

The Reporting Individual is the sole shareholder of the Reporting Entity. The Reporting Entity and the Reporting Individual are referred to herein collectively as the "Reporting Persons".

(b) Address of Principal Business Office or, if None, Residence:

The principal business office of each of the Reporting Persons is c/o Aurum Group, 16 Abba Hillel Road
Ramat Gan 5250608, Israel

(c) Citizenship:

The Reporting Entity is organized in Israel. The Reporting Individual is a citizen of the State of Israel.

(d) Title of Class of Securities

Ordinary Shares, New Israeli Shekel ("NIS") 0.01 par value per share ("Ordinary Shares")

(e) CUSIP Number

M96883109

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a)** Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b)** Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c)** Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d)** Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e)** An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f)** An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g)** A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h)** A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)** A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)** Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Not applicable.

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

With respect to each of the Reporting Persons:

- (a) Amount beneficially owned:** 4,254,778 Ordinary Shares
-

(b) Percent of class: 21.4%.*

*Such percentage is based on 19,898,674 Ordinary Shares of the Issuer that were issued and outstanding as of January 4, 2015 (which information appeared in the Issuer's proxy statement, dated January 6, 2015, for its extraordinary general meeting of shareholders that took place on February 11, 2015, which was annexed as Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K furnished by the Issuer to the SEC on January 6, 2015).

(c) Number of shares as to which the person has:

- (i) **Sole power to vote or to direct the vote:** Reporting Entity: 4,254,778
Reporting Individual: 0
- (ii) **Shared power to vote or to direct the vote:** Reporting Entity: 0
Reporting Individual: 4,254,778
- (iii) **Sole power to dispose or to direct the disposition of:** Reporting Entity: 4,254,778
Reporting Individual: 0
- (iv) **Shared power to dispose or to direct the disposition of:** Reporting Entity: 0
Reporting Individual: 4,254,778

By way of his ownership of all outstanding shares of the Reporting Entity, the Reporting Individual exercises shared voting and dispositive power with respect to all 4,254,778 Ordinary Shares that are held by the Reporting Entity and that are reported in this Statement.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. (See Item 5)

Not applicable.

Item 10. Certification.

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

AURUM VENTURES M.K.I. LTD.

By: /s/ Nili Lesnik
Name: Nili Lesnik
Title: Chief Executive Officer

By: /s/ Dan Gelvan
Name: Dan Gelvan
Title: Managing Director- Life Sciences

Date: February 17, 2015

/s/ Morris Kahn
MORRIS KAHN

Date: February 17, 2015

JOINT FILING AGREEMENT

In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13G to which this joint filing agreement is attached, and have duly executed this joint filing agreement as of the date set forth below.

AURUM VENTURES M.K.I. LTD.

By: /s/ Nili Lesnik
Name: Nili Lesnik
Title: Chief Executive Officer

By: /s/ Dan Gelvan
Name: Dan Gelvan
Title: Managing Director- Life Sciences

Date: February 17, 2015

/s/ Morris Kahn
MORRIS KAHN

Date: February 17, 2015
